ClinicalTrials.gg
RecruitingNCT07639333GRACEUpdated Oct 6, 2026

GRACE - Genetic Insights Into Early pRegnancy Loss Using Cell-free fEtal DNA

An interventional study of Non invasive prenatal test in Miscarriage in First Trimester and Prenatal Genetic Diagnosis, sponsored by Rennes University Hospital. Recruiting at 1 site in France. Open to female participants aged 18 Years to 43 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Rennes University Hospital · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years to 43 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 27 studies in Abortion, Spontaneous with a site in France — 7 open to participants now, 8 under way, none of them phase 3. Abortion, Spontaneous · France.

Planned enrollment
11th of 14
100 · median 210
Started
2026
with 1 other
No phase
12 of 27
5 open now
Registered
27th of 27
by date

Among the 27 studies in Abortion, Spontaneous with a site in France, this one is the 11th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2026, is one of 12 with no phase, and was the 27th registered.

Abortion, Spontaneous

221 studies on the registry are indexed under Abortion, Spontaneous; 44 are open to participants now.

Browse Abortion, Spontaneous studies →

Open to participants now

7 of the 27 studies in Abortion, Spontaneous with a site in France are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 36 Abortion, Spontaneous studies recruiting now, 11 (31%) set no upper age limit and 25 (69%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 43 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Abortion, Spontaneous with a site in France, or all of them as a file.
02

Study summary

The aim of this study is to assess the impact of non-invasive prenatal testing right after an early isolated miscarriage on mental health and on the patient's subsequent care in the year following the miscarriage

Read the detailed description

A blood sample will be added to primary care at the time of diagnosis of early miscarriage to realise non-invasive prenatal testing (NIPT). NIPT will be done on cell-free fetal DNA present in woman's blood to detect potential chromosomal abnormalities. At the 8-week consultation, the results will be shared with the patient if she so wishes. During this appointment, two questionnaires designed to assess her psychological state in relation to the miscarriage (HAD and PGS) will be completed. Depending on the patient's medical history and the results of the NIPT, a tailored care plan may be proposed. At the one-year follow-up appointment, the same questionnaires will be completed and a review will be carried out of the care proposed and provided, as well as the couple's future reproductive plans.

03

Conditions studied

  • Miscarriage in First Trimester
  • Prenatal Genetic Diagnosis

Browse trials for

Keywords

  • early miscarriage
  • miscarriage
  • prenatal diagnosis
  • prenatal test
  • cell free fetal DNA
  • chromosomal abnomarlities
04

Who can participate

Ages eligible
18 Years to 43 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A stopped pregnancy with an intrauterine pregnancy diagnosed by ultrasound (embryo larger than 7 mm corresponding to a gestational age of 6 weeks and 5 days. This is justified by the fact that fetal fragment (FF) detection is possible at 5 weeks of gestation, or 7 weeks and 5 days)
  • Expulsion of a pregnancy within the last 2 hours

    • Patient fluent in French
    • Enrolled in a social security program
    • Has received oral and written information about the protocol and has signed a consent form to participate in this research.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of an empty gestational sac, ectopic pregnancy, or unknown location
  • Ultrasound findings consistent with a molar pregnancy
  • Identified cause (preimplantation diagnosis, multiple uterine fibroids or a single fibroid > 5 cm, uterine malformation affecting the uterine cavity, lupus, and antiphospholipid syndrome)
  • Inability to obtain a blood sample
  • Known current malignant tumor
  • Blood transfusions within the last 3 months
  • Cell therapy or immunotherapy within the last 3 months
  • Previous organ transplant
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Patient

    Genetic: Non invasive prenatal test

Interventions

  • GeneticNon invasive prenatal test

    cell free fetal DNA analysis

06

What researchers measure

Primary outcomes

  1. Psychological distress score

    HADS (Hospital Anxiety and Depression Scale) and PGS (Perinatal Grief Scale) scores. The impact of the NIPT results will be analyzed in relation to these scores, which will be combined into a composite score of psychological distress. HADS questionnaire : Each item is rated on a four-point scale, giving maximum scores of 21 for anxiety and depression. Scores of 11 or more on either subscale are considered to be a significant 'case' of psychological morbidity, while scores of 8-10 represents 'borderline' and 0-7 'normal' The PGS is a self-report questionnaire designed to assess the emotional and psychological impact of perinatal loss, including miscarriage, stillbirth, or neonatal death. The more the score is high, the more the grief is intense.

    Time frame: 8 weeks

Secondary outcomes

  1. Long term Psychological distress score

    HADS (Hospital Anxiety and Depression Scale) and PGS (Perinatal Grief Scale) at 1 year. The impact of the DPNI results will be analyzed in relation to these scores, which will be combined into a composite score of psychological distress. HADS questionnaire : Each item is rated on a four-point scale, giving maximum scores of 21 for anxiety and depression. Scores of 11 or more on either subscale are considered to be a significant 'case' of psychological morbidity, while scores of 8-10 represents 'borderline' and 0-7 'normal' The PGS is a self-report questionnaire designed to assess the emotional and psychological impact of perinatal loss, including miscarriage, stillbirth, or neonatal death. The more the score is high, the more the grief is intense.

    Time frame: 12 months

  2. Rate of balanced chromosomal abnormalities in a parent

    Number of parents with a chromosomal rearrangement that explains the occurrence of an early miscarriage

    Time frame: 8 weeks

  3. Number of modified care pathways

    Number of modified care pathways based on the patient's etiology and the NIPT results during the year after miscarriages

    Time frame: 12 months

  4. Number of pregnancies

    Number of pregnancies and scalability during the year, according to care pathways and NIPT results

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All of the individual participant data collected during the trial will be available, after the primary publication of the results, to any researchers who provide a methodologically sound proposal. Proposals should be directed to dri@chu-rennes.fr. To gain access, data requestors will need to sign a data access agreement; depending on the case, additional formalities may be required.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Data availability after the primary publication of the results and until the database is deleted

Access criteria: Any researchers who provide a methodologically sound proposal will be able to access the IPD ans supporting information. To gain access, data requestors will need to sign a data access agreement; depending on the case, additional formalities may be required.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Mar 2028, 18 months after the start.

Of 43 non-industry interventional studies with no phase under Abortion, Spontaneous, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's planned 18 months is below that.

Counting every sponsor, half of 45 studies reached it within 27 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2026
First posted
Jun 10, 2026
StartActual
Sep 11, 2026
Primary completionEst.
Mar 2028
CompletionEst.
Jan 2029
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and date precision
1 update, last Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Minor edits only
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07639333
Responsible party
Sponsor
First posted
Jun 10, 2026
Start date
Sep 11, 2026
Primary completion
Mar 2028 (estimated)
Completion
Jan 2029 (estimated)
Last update
Oct 6, 2026

Study contacts

Marie-Laure Gervais
Contact
marie-laure.gervais@chu-rennes.fr
299282555 ext. +33
Marion Mercier, Md
study director · Rennes University Hospital
Vincent LAVOUE, Pr
study chair · Rennes University Hospital
Sylvie JAILLARD
study chair · Rennes University Hospital
Erika LAUNAY
study chair · Rennes University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion